Organ preservation Solutions Ltd (OPSL)
From securing IP protection and funding through to ongoing project management, Medipex has helped OPSL to set up and develop an innovative organ transplant solutions business.
The clinical need:
Effective preservation of transplant organs is critical for transplant success. The ageing population and increasing incidence of organ failure and chronic diseases are driving a need for advanced transplant solutions. Based on research from Leeds Teaching Hospitals NHS Trust, the first evidence-based innovation in organ preservation in decades has been developed: a solution that better preserves the quality and function of the organ over a longer period of time.
The innovation challenge:
The team at the NHS Trust needed funding and support to turn their research outputs into a product that could be used by clinical transplant teams globally.
How did Medipex help?
Medipex helped the team by securing intellectual property protection for the novel solution and supported with the set-up of a company (Organ Preservation Solutions Ltd, OPSL) that attracted investment from Brightstar Partners in 2015. Medipex has since supported OPSL with project management of the product development for over 5 years. Medipex also continued to provide support with intellectual property strategy, grant funding and identification of complementary technologies that could expand OPSL’s portfolio.
Impact:
The £2m investment brokered by Medipex, and the project management support, enabled OPSL to validate clinical needs, finalise product design, develop manufacturing and packaging processes and complete critical pre-clinical studies. Our recommendations helped to make strategic decisions regarding intellectual property protection, including additional patent filing and the next steps of commercialisation.
OPSL is currently seeking further investment to complete clinical studies and regulatory approvals.
Click to visit the OPSL website